D. Boral Capital Lowers Estrella Immunopharma (NASDAQ:ESLA) Price Target to $8.00

Estrella Immunopharma (NASDAQ:ESLA) had its price target lowered by equities research analysts at D. Boral Capital from $16.00 to $8.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Estrella Immunopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Stock Up 1.9%

Shares of ESLA opened at $1.08 on Wednesday. Estrella Immunopharma has a 52-week low of $0.73 and a 52-week high of $3.15. The company has a market capitalization of $40.79 million, a PE ratio of -3.18 and a beta of 0.55. The stock has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.41.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.